Patient responses to FST
| . | Overall, N = 58 . | FST . | P value . | |
|---|---|---|---|---|
| T-cell redirection, N = 19 . | Other, N = 39 . | |||
| Response to FST, n (%) | ||||
| Stringent complete response | 4 (7) | 4 (21) | 0 (0) | <.0001∗ |
| Complete response | 9 (15.5) | 8 (42) | 1 (3) | |
| VGPR | 4 (7) | 0 (0) | 4 (10) | |
| Partial response | 18 (31) | 4 (21) | 14 (36) | |
| Minimal response | 2 (3) | 0 (0) | 2 (5) | |
| Stable disease | 9 (15.5) | 1 (5) | 8 (20) | |
| Progressive disease | 12 (21) | 2 (11) | 10 (26) | |
| ORR on FST, n (%) | 35 (60) | 16 (84) | 19 (49) | .0095∗ |
| ORR on FST, 95% CI | 47-73 | 60-97 | 32-65 | |
| Clinical benefit rate on FST, n (%) | 37 (64) | 16 (84) | 21 (54) | .0239∗ |
| Clinical benefit rate on FST, 95% CI | 50-76 | 60-97 | 37-70 | |
| . | Overall, N = 58 . | FST . | P value . | |
|---|---|---|---|---|
| T-cell redirection, N = 19 . | Other, N = 39 . | |||
| Response to FST, n (%) | ||||
| Stringent complete response | 4 (7) | 4 (21) | 0 (0) | <.0001∗ |
| Complete response | 9 (15.5) | 8 (42) | 1 (3) | |
| VGPR | 4 (7) | 0 (0) | 4 (10) | |
| Partial response | 18 (31) | 4 (21) | 14 (36) | |
| Minimal response | 2 (3) | 0 (0) | 2 (5) | |
| Stable disease | 9 (15.5) | 1 (5) | 8 (20) | |
| Progressive disease | 12 (21) | 2 (11) | 10 (26) | |
| ORR on FST, n (%) | 35 (60) | 16 (84) | 19 (49) | .0095∗ |
| ORR on FST, 95% CI | 47-73 | 60-97 | 32-65 | |
| Clinical benefit rate on FST, n (%) | 37 (64) | 16 (84) | 21 (54) | .0239∗ |
| Clinical benefit rate on FST, 95% CI | 50-76 | 60-97 | 37-70 | |
P value < .05.